Aptose to Participate in Canaccord Genuity’s 2023 Horizons in Oncology Virtual Conference
10. April 2023 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, April 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Biosciences to Participate in Cantor’s The Future of Oncology Virtual Symposium
28. März 2023 16:01 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 28, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Reports Results for the Fourth Quarter and Full Year 2022
23. März 2023 16:44 ET
|
Aptose Biosciences, Inc.
─ APTIVATE Expansion Trial of Tuspetinib as Single Agent in Relapsed/Refractory AML Patients is Up and Running; Initiated Enrollment of Combination Treatment Arm with Venetoclax ─ ─ RAS Mutated AML...
Aptose Reports Immaterial Financial Exposure to Silicon Valley Bank
10. März 2023 18:44 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 10, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose to Report Fourth Quarter and Full Year 2022 Financial Results and Hold Conference Call on Thursday, March 23, 2023
09. März 2023 16:05 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 09, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences to Present at Oppenheimer 33rd Annual Healthcare Conference
02. März 2023 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, March 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Initiates Dosing of Tuspetinib in APTIVATE Expansion Trial in Patients with Acute Myeloid Leukemia
30. Januar 2023 07:00 ET
|
Aptose Biosciences, Inc.
• AML Patients Receive Tuspetinib Monotherapy to Kick Off APTIVATE Phase 1/2 Trial• New Response Emerges with 40 mg Tuspetinib in FLT3 Wildtype AML Patient• Aptose Elucidates Rationale for...
Aptose Biosciences to Present at Biotech Showcase™ 2023 Conference
28. Dezember 2022 07:30 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 28, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage precision oncology company developing highly differentiated oral kinase...
Aptose Biosciences Establishes New At-The-Market Facility
12. Dezember 2022 06:15 ET
|
Aptose Biosciences, Inc.
SAN DIEGO and TORONTO, Dec. 12, 2022 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (“Aptose” or the “Company”) (NASDAQ: APTO, TSX: APS), a clinical-stage precision oncology company developing highly...
Aptose Announces Updated Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations
11. Dezember 2022 09:00 ET
|
Aptose Biosciences, Inc.
Company Provides Comprehensive Clinical Update from Phase 1/2 TrialTuspetinib Continues to Deliver Single Agent Responses in r/r AML PatientsTuspetinib Safety and Efficacy Profile may Position Drug to...